Mumbai: Venus Remedies has announced that the Drug Controller General of India has granted approval for the launch of its fourth innovative R&D developed fixed dose combination (FDC) drug of its latest generation cephalosporin with an amino-glycoside
The company is launching the innovative therapy for APE / Cystis Fibrosis patients after completing the multi-centred Phase II Clinical Trials.
Venus Remedies said the commercial launch of the drug would be a boon for those suffering from cystis fibrosis as it was the only solution for the treatment of infections caused by P Aeruginosa / MRSA, a fatal disease spreading rapidly around the world with no sure treatment at present.
Venus says it plans to launch the drug commercially "very soon" in strategic marketing tie-up with leading Indian pharma companies in the Indian market.
The com[pany expects the drug to become a segment leader within two years of its launch and says it has already filed patent applications in 50 countries, where this product will be registered by the company, for protection of its patent rights after it is launched in the $2.5 billion global market.
The company stated that the drug belongs to the cephalosporins group of generic drugs. The company is also tying up with Indian pharmaceutical companies for strategic marketing of drugs and has filed patent applications in 50 countries.